Retinal Pigment Epithelium Atrophy in Recessive Stargardt Disease as Measured by Short-Wavelength and Near-Infrared Autofluorescence.

Szczegóły
Abstrakt

Tytuł:: Retinal Pigment Epithelium Atrophy in Recessive Stargardt Disease as Measured by Short-Wavelength and Near-Infrared Autofluorescence.
Autorzy:: Jauregui R; Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.; Jonas Children's Vision Care, New York, NY, USA.
Nuzbrokh Y; Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.; Jonas Children's Vision Care, New York, NY, USA.
Su PY; Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.
Zernant J; Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.
Allikmets R; Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.; Department of Pathology & Cell Biology, Columbia University Medical Center, New York, NY, USA.
Tsang SH; Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.
Sparrow JR; Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.
Źródło:: Translational vision science & technology [Transl Vis Sci Technol] 2021 Jan 05; Vol. 10 (1), pp. 3. Date of Electronic Publication: 2021 Jan 05 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Rockville, Md. : Association for Research in Vision and Ophthalmology
MeSH Terms:: Retinal Pigment Epithelium*/pathology
Tomography, Optical Coherence*
Atrophy/pathology ; Fluorescein Angiography ; Humans ; Stargardt Disease
References:: Invest Ophthalmol Vis Sci. 2014 Oct 23;55(12):8134-43. (PMID: 25342616)
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3556-64. (PMID: 16877429)
Retina. 2014 Mar;34(3):576-82. (PMID: 24056526)
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):5024-9. (PMID: 24707049)
Invest Ophthalmol Vis Sci. 2012 Jul 03;53(8):4458-67. (PMID: 22661473)
Hum Mol Genet. 2004 Mar 1;13(5):525-34. (PMID: 14709597)
Ophthalmol Retina. 2017 Nov - Dec;1(6):514-523. (PMID: 31047445)
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5867-71. (PMID: 19578016)
Ophthalmology. 2003 Jun;110(6):1151-8. (PMID: 12799240)
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):13. (PMID: 32298433)
Retina. 2019 Jul;39(7):1399-1409. (PMID: 29642238)
Invest Ophthalmol Vis Sci. 2014 May 01;55(5):2841-52. (PMID: 24677105)
JAMA Ophthalmol. 2017 Nov 1;135(11):1232-1241. (PMID: 29049437)
Am J Ophthalmol. 2012 Jul;154(1):146-54. (PMID: 22464366)
Nat Genet. 1997 Mar;15(3):236-46. (PMID: 9054934)
J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1457-67. (PMID: 17429493)
Exp Eye Res. 2009 Jun 15;89(1):16-24. (PMID: 19217903)
JAMA Ophthalmol. 2019 Aug 1;:. (PMID: 31369039)
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):5029-39. (PMID: 26230768)
Ophthalmology. 1987 Jul;94(7):809-14. (PMID: 3658351)
Invest Ophthalmol Vis Sci. 2015 May;56(5):3226-34. (PMID: 26024107)
Am J Ophthalmol. 2018 Oct;194:120-125. (PMID: 30053465)
Invest Ophthalmol Vis Sci. 2013 Dec 17;54(13):8181-90. (PMID: 24265018)
J Neurosci Res. 2019 Jan;97(1):98-106. (PMID: 29701254)
Genet Med. 2019 Oct;21(10):2336-2344. (PMID: 30926958)
Ophthalmology. 2019 Sep;126(9):1288-1296. (PMID: 31227323)
Invest Ophthalmol Vis Sci. 1995 Mar;36(3):718-29. (PMID: 7890502)
Exp Eye Res. 2010 Aug;91(2):143-52. (PMID: 20398653)
Transl Vis Sci Technol. 2020 Jun 25;9(7):33. (PMID: 32832238)
Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):585-91. (PMID: 23287793)
Am J Ophthalmol. 2009 May;147(5):895-902, 902.e1. (PMID: 19243736)
Transl Vis Sci Technol. 2019 Dec 20;8(6):46. (PMID: 31879568)
Ophthalmic Genet. 2009 Jun;30(2):69-75. (PMID: 19373677)
Cell. 1999 Jul 9;98(1):13-23. (PMID: 10412977)
Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7640-6. (PMID: 21873669)
Genet Med. 2017 Feb;19(2):249-255. (PMID: 27854360)
Grant Information:: R01 EY024091 United States EY NEI NIH HHS; R01 EY028954 United States EY NEI NIH HHS; R01 EY028203 United States EY NEI NIH HHS; R01 EY029315 United States EY NEI NIH HHS; P30 EY019007 United States EY NEI NIH HHS
Contributed Indexing:: Keywords: Stargardt disease; near-infrared autofluorescence; short-wavelength autofluorescence
Entry Date(s):: Date Created: 20210128 Date Completed: 20210628 Latest Revision: 20210628
Update Code:: 20240105
PubMed Central ID:: PMC7794276
DOI:: 10.1167/tvst.10.1.3
PMID:: 33505770
: Czasopismo naukowe

Full Text Finder

Purpose: To compare the detection of retinal pigment epithelium (RPE) atrophy in short-wavelength (SW-AF) and near-infrared autofluorescence (NIR-AF) images in Stargardt disease (STGD1) patients.
Methods: SW-AF and NIR-AF images (115 eyes from 115 patients) were analyzed by two independent graders. Hypoautofluorescent (hypoAF) areas, indicative of RPE atrophy, were measured, and the two modalities were compared.
Results: Patients were segregated into four groups: nascent (6 [5%]), widespread (21 [18%]), discrete (55 [48%]), and chorioretinal atrophy (33 [29%]). The areas of hypoAF were larger in NIR-AF compared to SW-AF images in discrete (3.9 vs. 2.2 mm 2 , P < 0.001) and chorioretinal atrophy (12.7 vs. 11.4 mm 2 , P = 0.015). Similar findings were observed qualitatively in nascent and widespread atrophy patients. Using the area linear model (ALM), lesion area increased at similar rates in SW-AF and NIR-AF images of discrete atrophy (0.20 vs. 0.32 mm 2 /y, P = 0.275) and chorioretinal atrophy (1.30 vs. 1.74 mm 2 /y, P = 0.671). Using the radius linear model (RLM), the lesion effective radius also increased similarly in SW-AF and NIR-AF images in discrete (0.03 vs. 0.05 mm 2 /y, P = 0.221) and chorioretinal atrophy (0.08 vs. 0.10 mm 2 /y, P = 0.754) patients.
Conclusions: NIR-AF reveals a larger area of RPE atrophy in STGD1 patients compared to SW-AF images, but rates of lesion enlargement in the two modalities are similar.
Translational Relevance: Measurements of RPE atrophy by AF imaging are crucial for monitoring STGD1 disease progression and given our findings we advocate greater use of NIR-AF for patients.
Competing Interests: Disclosure: R. Jauregui, None; Y. Nuzbrokh, None; P.-Y. Su, None; J. Zernant, None; R. Allikmets, None; S.H. Tsang, None; J.R. Sparrow, None
(Copyright 2021 The Authors.)

Informacja